A trial comparing chemotherapy and bevacizumab with chemotherapy alone and a feasibility study looking at lapatinib for HER2 positive cancer (ST03)

Overview

Cancer types:

Oesophageal cancer, Stomach cancer

Status:

Results

Phase:

Phase 2/3

Details

This trial compared chemotherapy and bevacizumab with chemotherapy on its own as a treatment both before and after surgery. It was open to people with:

At some hospitals another part of the trial looked at lapatinib for people who had cancer that was HER2 positive. This part was a feasibility study.

Cancer Research UK supported this trial.

Recruitment start: 31 October 2007

Recruitment end: 16 June 2017

How to join

Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.

Chief investigators

Professor David Cunningham

Supported by

Cancer Research UK

Experimental Cancer Medicine Centre (ECMC)

GlaxoSmithKline (GSK)

Novartis

Medical Research Council (MRC)

NIHR Clinical Research Network: Cancer

Roche

Other information

This is Cancer Research UK trial number CRUK/06/025.

Last reviewed: 09 Sept 2020

CRUK internal database number: 703

Dangoor Education

About Cancer generously supported by Dangoor Education since 2010. Learn more about Dangoor Education

Help and support

Questions for your doctor

What to ask your doctor about clinical trials.

Cancer chat forum

Meet and chat to other cancer people affected by cancer.

Nurse helpline

Questions about cancer? Call freephone 0808 800 40 40 from 9 to 5 - Monday to Friday. Alternatively, you can email us.